Krystal Biotech
KRYS
90 hedge funds and large institutions have $502M invested in Krystal Biotech in 2020 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 35 increasing their positions, 28 reducing their positions, and 12 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
25% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 28
17% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 12
0.49% more ownership
Funds ownership: 66.17% → 66.66% (+0.49%)
0% more funds holding
Funds holding: 90 → 90 (0)
21% less capital invested
Capital invested by funds: $635M → $502M (-$133M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$23.6M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$15.7M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$13.1M |
| 4 |
CWG
C WorldWide Group
Copenhagen,
Denmark
|
+$7.1M |
| 5 |
Aviva
London,
United Kingdom
|
+$4.86M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$55.1M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$8.25M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$4.78M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
-$4.61M |
| 5 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$3.33M |
KRYS Hedge Fund Activity: Q1 2020 in Review
90 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Krystal Biotech (KRYS) for Q1 2020, worth a combined $502M — down 21% from $635M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new KRYS positions and 12 closed out — a net gain of 2 holders — while 35 added to existing stakes and 28 trimmed.
The largest buyer was Consonance Capital Management, adding an estimated $23.6M. The largest seller was OrbiMed, exiting entirely with an estimated $55.1M sold.
- 90 institutional investors held Krystal Biotech (KRYS) as of Q1 2020, unchanged from Q4 2019.
- Funds reported $502M of Krystal Biotech stock for Q1 2020, down 21% quarter-over-quarter.
- 14 funds opened new Krystal Biotech positions in Q1 2020 and 12 closed out, a net change of +2 holders.
- The largest Krystal Biotech buyer in Q1 2020 was Consonance Capital Management, an estimated $23.6M added.
- The largest Krystal Biotech seller in Q1 2020 was OrbiMed, an estimated $55.1M sold.
Based on aggregated 13F filings for Q1 2020.